BioMarin Highlights Advances In Orphan Drug Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
BioMarin highlighted research in several rare disease areas at an Oct. 19 R&D day, its first in over two years. Increasingly, drug development for rare disorders such as Gaucher or Pompe disease is an attractive area for even the biggest pharmaceutical players, in part because of the potentially lower regulatory and reimbursement hurdles associated with developing therapies to treat disorders where there is such great unmet medical need.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.